Anne Prener - 01 Jul 2026 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Director
Issuer ticker: KROS
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jul 2026, 16:31:00 UTC
Prior SEC filing: 20 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Esther Cho, Attorney-in-Fact

Key filing fact

Anne Prener filed Form 4 for Keros Therapeutics, Inc. (KROS) on 06 Jul 2026.

Key facts

This page summarizes Anne Prener's Form 4 filing for Keros Therapeutics, Inc. (KROS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jul 2026, 16:31.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001797917 Primary reporting owner

Prener Anne

Relationship: Director
Address: C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON
Signature: /s/ Esther Cho, Attorney-in-Fact
Signature date: 06 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KROS transaction

Common Stock

Award

Transaction value
Shares: +13,786
Change %
Price: $0.000000^*
Shares after: 13,786
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KROS transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +14,870
Change %
Price: $0.000000^*
Shares after: 14,870
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,870
Exercise price: $10.88
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a restricted stock unit ("RSU") award. The RSUs shall vest over a three-year period in twelve equal quarterly installments with the first such vesting to occur on August 15, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Footnote F2

The shares subject to the option shall vest over a three-year period in equal quarterly installments with the first such vesting to occur on October 1, 2026, subject to the Reporting Person's continuous service through each such vesting date.